Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Nutrient excess, a major driver of obesity, diminishes hypothalamic responses to exogenously administered leptin, a critical hormone of energy balance. Here, we aimed to identify a physiological signal that arises from excess caloric intake and negatively controls hypothalamic leptin action. We found that deficiency of the gastric inhibitory polypeptide receptor (Gipr) for the gut-derived incretin hormone GIP protected against diet-induced neural leptin resistance. Furthermore, a centrally administered antibody that neutralizes GIPR had remarkable antiobesity effects in diet-induced obese mice, including reduced body weight and adiposity, and a decreased hypothalamic level of SOCS3, an inhibitor of leptin actions. In contrast, centrally administered GIP diminished hypothalamic sensitivity to leptin and increased hypothalamic levels of Socs3. Finally, we show that GIP increased the active form of the small GTPase Rap1 in the brain and that its activation was required for the central actions of GIP. Altogether, our results identify GIPR/Rap1 signaling in the brain as a molecular pathway linking overnutrition to the control of neural leptin actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, it has been suggested that, in obesity, elevated circulating GIP levels lead to the activation of EPAC/Raf1 signaling and this is an important condition for inducing neural leptin resistance [43].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetics of Food Intake Self-Regulation in Childhood: Literature Review and Research Opportunities
Faith, M. S., Carnell, S., & Kral, T. V. E. (2013) · Human Heredity · doi:10.1159/000353879 · Cited by 7,601
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534 · cited 11×
“In contrast, under HFD conditions, WT mice did not exhibit these responses to leptin, demonstrating the expected diminished leptin response induced by HFD feeding; Gipr-KO mice, however, retained their sensitivity to leptin (Figure 2B).”
BackgroundInfluentialAssociation analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Hypothalamic IKKβ/NF-κB and ER Stress Link Overnutrition to Energy Imbalance and Obesity
Zhang, X., Zhang, G., Zhang, H., Karin, M., Bai, H., & Cai, D. (2008) · Cell · doi:10.1016/j.cell.2008.07.043 · Cited by 1,350
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 5×
“Since endogenous GIP is produced in K cells in the upper gut and GIP levels are reported to be elevated in diet-induced obesity, reaching 20–100 pM (9, 14, 24, 25), we next determined whether increasing the peripheral levels of GIP inhibits neural leptin actions.”
BackgroundInfluentialCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Endoplasmic Reticulum Stress Plays a Central Role in Development of Leptin Resistance
Ozcan, L., Ergin, A. S., Lu, A., Chung, J., Sarkar, S., Nie, D., Myers, M. G., & Ozcan, U. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2008.12.004 · Cited by 875 · cited 1×
“Excess calorie intake provokes hypothalamic activation of multiple inflammatory and stress response pathways, such as IKB kinase-β/ NF-κB (IKKβ/NF-κB) signaling (1), TLR4 signaling (2), unfolded protein response (UPR) signaling (3), and exchange protein directly activated by cAMP (EPAC)/Rap1 GTPase (EPAC/Rap1) signali…”
BackgroundFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
Speliotes, E. K., Willer, C. J., Berndt, S. I., Monda, K. L., Þorleifsson, G., Jackson, A., Allen, H. L., Lindgren, C. M., Luan, J., Mägi, R., et al. (2010) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/d3bn-7g86 · Cited by 767
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Anatomical Profiling of G Protein-Coupled Receptor Expression
Regard, J. B., Sato, I. T., & Coughlin, S. R. (2008) · Cell · doi:10.1016/j.cell.2008.08.040 · Cited by 693 · cited 1×
“Results and Discussion First, we confirmed Gipr expression in the brain (22) (Supplemental Figure 1, A–C; supplemental material available online with this article; doi:10.”
BackgroundKleinridders, A., Schenten, D., Könner, A. C., Belgardt, B. F., Mauer, J., Okamura, T., Wunderlich, F. T., Medzhitov, R., & Brüning, J. C. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.013 · Cited by 483 · cited 1×
“Excess calorie intake provokes hypothalamic activation of multiple inflammatory and stress response pathways, such as IKB kinase-β/ NF-κB (IKKβ/NF-κB) signaling (1), TLR4 signaling (2), unfolded protein response (UPR) signaling (3), and exchange protein directly activated by cAMP (EPAC)/Rap1 GTPase (EPAC/Rap1) signali…”
BackgroundTurcot, V., Lu, Y., Highland, H. M., Schurmann, C., Justice, A. E., Fine, R. S., Bradfield, J. P., Esko, T., Giri, A., Graff, M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0011-x · Cited by 409 · cited 12×
“We found that the inhibitory effect of GIP was completely blocked with either ESI-05, an EPAC2-specific inhibitor (Figure 3C), or ESI-09, a specific inhibitor for both EPAC1 and EPAC2 (data not shown), but the inhibitory effect of GIP was not affected by the PKA inhibitor PKI14–22 (Figure 3D) or H89 (Supplemental Figu…”
BackgroundInfluentialExtrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237 · cited 3×
“In agreement with a recent study (21), peripheral administration of Gipg013 did not reduce weight from the baseline but merely prevented weight gain in HFD-induced obese mice (Supplemental Figure 2, C–F).”
BackgroundOptimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Creutzfeldt, W., Ebert, R., Willms, B., Frerichs, H., & Brown, J. C. (1978) · Diabetologia · doi:10.1007/bf00429703 · Cited by 211 · cited 2×
“Since endogenous GIP is produced in K cells in the upper gut and GIP levels are reported to be elevated in diet-induced obesity, reaching 20–100 pM (9, 14, 24, 25), we next determined whether increasing the peripheral levels of GIP inhibits neural leptin actions.”
BackgroundNasteska, D., Harada, N., Suzuki, K., Yamane, S., Hamasaki, A., Joo, E., Iwasaki, K., Shibue, K., Harada, T., & Inagaki, N. (2014) · Diabetes · doi:10.2337/db13-1563 · Cited by 171
Molecular mechanisms underlying nutrient-stimulated incretin secretion
Parker, H. E., Reimann, F., & Gribble, F. M. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940900132x · Cited by 155
TCF1 links GIPR signaling to the control of beta cell function and survival
Campbell, J. E., Ussher, J. R., Mulvihill, E. E., Kolic, J., Baggio, L. L., Cao, X., Liu, Y., Lamont, B. J., Morii, T., Streutker, C. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.3997 · Cited by 142 · cited 2×
“Since endogenous GIP is produced in K cells in the upper gut and GIP levels are reported to be elevated in diet-induced obesity, reaching 20–100 pM (9, 14, 24, 25), we next determined whether increasing the peripheral levels of GIP inhibits neural leptin actions.”
BackgroundK-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease
Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 110
Joo, E., Harada, N., Yamane, S., Fukushima, T., Taura, D., Iwasaki, K., Sankoda, A., Shibue, K., Harada, T., Suzuki, K., et al. (2017) · Diabetes · doi:10.2337/db16-0758 · Cited by 104
Holscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102
Abnormalities of GIP in Spontaneous Syndromes of Obesity and Diabetes in Mice
Flatt, P. R., Bailey, C. J., Kwasowski, P., Swanston-Flatt, S. K., & Marks, V. (1983) · Diabetes · doi:10.2337/diab.32.5.433 · Cited by 101 · cited 2×
“Since endogenous GIP is produced in K cells in the upper gut and GIP levels are reported to be elevated in diet-induced obesity, reaching 20–100 pM (9, 14, 24, 25), we next determined whether increasing the peripheral levels of GIP inhibits neural leptin actions.”
BackgroundPorter, D. W., Irwin, N., Flatt, P. R., Hölscher, C., & Gault, V. A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.059 · Cited by 93
Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O’Brien, S., Collinson, A., Papworth, M. A., Fredin, M. F., Jermutus, L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426288 · Cited by 87 · cited 1×
“To examine the potential role of brain GIPR, we assessed the direct impact of acute inhibition of brain GIPR on obesity by centrally infusing the neutralizing monoclonal antibody Gipg013, which is a highly specific and potent antagonist of GIPR with a fully characterized mode of action (23).”
BackgroundSelf-citationInduction of Leptin Resistance by Activation of cAMP-Epac Signaling
Fukuda, M., Williams, K. W., Gautron, L., & Elmquist, J. K. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.016 · Cited by 75 · cited 1×
“As previously shown (29), leptin robustly induced hypothalamic p-STAT3 levels in brain slices (Figure 3, A and B, and Supplemental Figure 8A).”
BackgroundSelf-citationFaivre, É., Hamilton, A., & Hölscher, C. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.007 · Cited by 73
Enhanced Cortico-Amygdala Efficacy and Suppressed Fear in Absence of Rap1
Pan, B.-X., Vautier, F., Ito, W., Bolshakov, V. Y., & Morozov, A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5156-07.2008 · Cited by 64 · cited 1×
“To conclusively test this, we centrally injected GIP into mice with Rap1 deficiency in the forebrain, including multiple hypothalamic nuclei (Rap1ΔCNS) (4, 30), or into control mice.”
MethodNeuronal Rap1 Regulates Energy Balance, Glucose Homeostasis, and Leptin Actions
Kaneko, K., Xu, P., Cordonier, E. L., Chen, S. S., Ng, A., Xu, Y., Morozov, A., & Fukuda, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.039 · Cited by 49 · cited 3×
“Excess calorie intake provokes hypothalamic activation of multiple inflammatory and stress response pathways, such as IKB kinase-β/ NF-κB (IKKβ/NF-κB) signaling (1), TLR4 signaling (2), unfolded protein response (UPR) signaling (3), and exchange protein directly activated by cAMP (EPAC)/Rap1 GTPase (EPAC/Rap1) signali…”
BackgroundMethodSelf-citationIs there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 47
Bates, H. E., Campbell, J. E., Ussher, J. R., Baggio, L. L., Maida, A., Seino, Y., & Drucker, D. J. (2012) · Diabetes · doi:10.2337/db11-1060 · Cited by 43
Cited by
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
Role of the gut-brain axis in energy and glucose metabolism
Wachsmuth, H. R., Weninger, S. N., & Duca, F. A. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00677-w · Cited by 269
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
“A key finding of the current study is that tirzepatide ameliorated peripheral IR in a model of DIO.”
BackgroundBeyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“Central intracerebroventricular administration of the Gipg013 antagonist also reduces body weight and adiposity in mice with diet-induced obesity, findings associated with decreased hypothalamic levels of SOCS3, an inhibitor of leptin signalling 144 .”
Metadata
- Authors
- Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., Xu, P., Chen, S. S., Chen, M.-H., Xu, Y., Williams, K. W., Ravn, P., & Fukuda, M.
- Affiliations
- Baylor College of Medicine (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Corresponding author
- Fukuda, Makoto
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2019-08-12
- Volume
- 129
- Issue
- 9
- Pages
- 3786-3791
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6715359
- OpenAlex
- W2967571306
- Cited by
- 106
- References
- 33
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 15 · 2023: 11 · 2022: 16 · 2021: 15 · 2020: 10 · 2019: 12
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- NIH (5R01DK104901, P30-DK079638, DK119169, T32HD071839)
- USDA/CRIS (ARS6250-51000-055, 6250-51000-059)
- AHA (14BGIA20460080, 15POST22500012, 13POST13800000, 15POST22670017)
- NIDDK (DK56338)
- NCI (CA125123)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, Rap1, leptin resistance, hypothalamus, overnutrition, diet-induced obesity, SOCS3, gut-brain signaling, incretins, energy balance, adiposity
- MeSH terms
- Suppressor of Cytokine Signaling 3 Protein, Animals, Hypothalamus, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Leptin, rap1 GTP-Binding Proteins, Adiposity, Mice, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.